- ¥2980
- LMAI Bio
- LM-5241R-FITC
- 中国/美国/欧洲
- 2025年07月09日
- IF=1:50-200
- Human, Rat,
- Human, Rat,
10 年钻石会员
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 供应商：
上海联迈生物工程有限公司
- 库存：
大量
- 靶点：
详见说明书
- 级别：
1
- 目录编号：
LM-5241R-FITC
- 克隆性：
多克隆
- 抗原来源：
Rabbit
- 保质期：
1年
- 抗体英文名：
Anti-Phospho-Caspase-9 (Ser196)/FITC
- 抗体名：
Anti-Phospho-Caspase-9 (Ser196)/FITC
- 标记物：
FITC标记
- 宿主：
Human, Rat,
- 适应物种：
Human, Rat,
- 免疫原：
详见说明书
- 亚型：
IGg
- 形态：
粉末、液体、冻干粉
- 应用范围：
IF=1:50-200
- 浓度：
1mg/ml
- 保存条件：
-20 °C
- 规格：
100ul
FITC标记的磷酸化半胱氨酸蛋白酶9抗体
| 英文名称 | Anti-Phospho-Caspase-9 (Ser196)/FITC |
| 中文名称 | FITC标记的磷酸化半胱氨酸蛋白酶9抗体 |
| 别 名 | APAF 3; APAF3; Apoptosis related cysteine peptidase; Apoptotic protease activating factor 3; Apoptotic protease Mch 6; CASP 9; CASP9; Caspase 9 Dominant Negative; Caspase 9 precursor; Caspase 9c; Caspase9; EC 3.4.22.; ICE LAP6; ICE like apoptotic protease 6; MCH6 antibody RNCASP9; CASP9_HUMAN. |
| 规格价格 | 100ul/2980元 购买 大包装/询价 |
| 说 明 书 | 100ul |
| 产品类型 | 磷酸化抗体 |
| 研究领域 | 肿瘤 免疫学 |
| 抗体来源 | Rabbit |
| 克隆类型 | Polyclonal |
| 交叉反应 | Human, Rat, |
| 产品应用 | IF=1:50-200 not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 35kDa |
| 性 状 | Lyophilized or Liquid |
| 浓 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated Synthesised phosphopeptide derived from human CASP9 around the phosphorylation site of Ser196 |
| 亚 型 | IgG |
| 纯化方法 | affinity purified by Protein A |
| 储 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存条件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
| 产品介绍 | background: Caspase 9 (also known as ICE like apoptotic protease 6 (ICE LAP6), apoptotic protease Mch6, and apoptotic protease activating factor 3 (Apaf3)) is a member of the peptidase family C14 that contains a CARD domain. This caspase is active as a heterotetramer and has been reported to have two isoforms. ProCaspase 9 has been reported to be approximately 47 kD. This caspase is present in the cytosol and, upon activation, translocates to the mitochondria. Caspase 9 is involved in the caspase activation cascade responsible for apoptosis execution and cleaves/activates Caspase 3 and Caspase 6. Caspase 9 is inhibited by the dominant negative isoform, BclXL, cIAP1, cIAP2, XIAP, and Livin. This caspase becomes activated when recruited to Apaf1/cytochrome c complex, and following cleavage by Apaf1, granzyme B, Caspase 3, possibly Caspase 8 and Caspase 10 into large p37 and small p10 subunits. Caspase 9 intereacts with BIRC7 and has been shown to cleave PARP and vimentin. Function: Involved in the activation cascade of caspases responsible for apoptosis execution. Binding of caspase-9 to Apaf-1 leads to activation of the protease which then cleaves and activates caspase-3. Proteolytically cleaves poly(ADP-ribose) polymerase (PARP). Isoform 2 lacks activity is an dominant-negative inhibitor of caspase-9. Subunit: Heterotetramer that consists of two anti-parallel arranged heterodimers, each one formed by a 35 kDa (p35) and a 10 kDa (p10) subunit. Caspase-9 and APAF1 bind to each other via their respective NH2-terminal CED-3 homologous domains in the presence of cytochrome C and ATP. Interacts with the inhibitors BIRC2, BIRC4, BIRC5 and BIRC7. Interacts (inactive form) with EFHD2. Interacts with HAX1. Tissue Specificity: Ubiquitous, with highest expression in the heart, moderate expression in liver, skeletal muscle, and pancreas. Low levels in all other tissues. Within the heart, specifically expressed in myocytes. Post-translational modifications: Cleavages at Asp-315 by granzyme B and at Asp-330 by caspase-3 generate the two active subunits. Caspase-8 and -10 can also be involved in these processing events. Phosphorylated at Thr-125 by MAPK1/ERK2. Phosphorylation at Thr-125 is sufficient to block caspase-9 processing and subsequent caspase-3 activation. Similarity: Belongs to the peptidase C14A family. Contains 1 CARD domain. Database links: UniProtKB/Swiss-Prot: P55211.3 Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. Caspase-9半胱氨酸蛋白酶家族成员之一，又称ICE-Lap6（ICE Like apoptotease 6）参与细胞凋亡过程和细胞因子的加工过程，在许多胚胎和成人组织中都有分布。此抗体主要用于肿瘤凋亡的研究。 |
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验相关实验
当FITC在碱性溶液中与抗体蛋白反应时，主要是蛋白质上赖氨酸的r氨基与荧光素的硫碳胺键(thiocarbmide)结合，形成FITC-蛋白质结合物，即荧光抗体或荧光结合物。一个IgG分子中有86个赖氨酸残基，一般最多能结合15～20个，一个IgG分子可结合2～8个分子的FITC，其反应式如下FITC-N=C=S + N-H2-蛋白质 → FITC-NS-C-N-H2-蛋白质常用Marsshall(1958)法标记荧光抗体，也可以根据条件采用Chadwick等标记法或Clark
ml三蒸水中即成； 方法与步骤： 根据Marshall氏法高效价的抗人球蛋白兔免疫血清，分离球蛋白。 1. 用0.15 mol/L NaCl的盐水及0.15 mol/L pH9.0的NaHCO3-Na2CO3缓冲液稀释使每毫升内含抗体10mg，缓冲液为总量的10%； 2. 将以上溶液降温至4℃，按蛋白：荧光素=50—80mg：1mg的比例加入异硫氰酸荧光素，在0—4℃下电磁搅拌12—14h； 3.用半饱和硫酸铵将标记球蛋白
5. 过柱。取透析过夜的标记物，过葡萄糖凝胶G-25或G-50柱，分离出游离荧光素，收集标记的荧光抗体进行鉴定。
技术资料暂无技术资料 索取技术资料
FITC标记的磷酸化半胱氨酸蛋白酶9抗体
¥2980
